| abstract |
The invention relates to glycogen synthase kinase-3 inhibitors (for example, GSKβ or GSKα inhibitors) for use in the therapy of a T-cell mediated disease in an individual in need thereof. T-cell mediated disease may be a disease associated with loss of immunosuppressive function of Tregs, for example, immune disease or autoimmune disease such as, for example, immunodeficiency, primary immunodeficiency disease ( MIP), type I diabetes, systemic lupus erythematosus (SLE), asthma, colitis, psoriasis, bronchiectasis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura (ITP), or combinations of those -this. The compositions and / or methods of the invention may be used to enhance, prevent or reduce the severity and / or progression of any of the above-mentioned diseases. |